News

Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate

1 February 2024

Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces initiation of coverage by EuroLand Corporate.

In a study entitled L’imagerie cellulaire à la loupe, EuroLand Corporate recommends Mauna Kea shares to Buy, with a target price of €0.71, representing an increase of +56% compared with the share’s closing price on January 31, 2024 (€0.456).

This new study adds to the consensus of financial analysts who already covers the stock alongside Portzamparc and Gilbert Dupont.

Latest News

Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 

Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 

No results found.